KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Revenue (2019 - 2025)

Esperion Therapeutics (ESPR) has disclosed Revenue for 7 consecutive years, with $168.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 143.73% year-over-year to $168.4 million, compared with a TTM value of $403.1 million through Dec 2025, up 21.31%, and an annual FY2025 reading of $403.1 million, up 21.31% over the prior year.
  • Revenue was $168.4 million for Q4 2025 at Esperion Therapeutics, up from $87.3 million in the prior quarter.
  • Across five years, Revenue topped out at $168.4 million in Q4 2025 and bottomed at $8.0 million in Q1 2021.
  • Average Revenue over 5 years is $50.3 million, with a median of $33.1 million recorded in 2023.
  • The sharpest move saw Revenue plummeted 80.84% in 2021, then soared 466.14% in 2024.
  • Year by year, Revenue stood at $15.4 million in 2021, then rose by 22.19% to $18.8 million in 2022, then soared by 71.38% to $32.2 million in 2023, then surged by 114.3% to $69.1 million in 2024, then surged by 143.73% to $168.4 million in 2025.
  • Business Quant data shows Revenue for ESPR at $168.4 million in Q4 2025, $87.3 million in Q3 2025, and $82.4 million in Q2 2025.